CSBio CSBio

X
[{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces $10 Million Bought Deal Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives Two US Patents Covering Opaganib For Ebola virus & RHB-104 for Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elgan Pharma Announces Positive Results from its Phase III Study of ELGN-GI in Preterm Infants for Treatment of Intestinal Malabsorption","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Elgan Pharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA\u00ae) for Oncology Support","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill's RHB-102 (BEKINDA\u00ae) and Opaganib Granted New Patents in Oncology Setting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"ELGAN Pharma Awarded $2.5 Million EU Grant to Support Phase III Registrational Study of ELGN-GI for the Treatment of Intestinal Malabsorption in Preterm Infants","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Elgan Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The grant will support the Phase III registrational study of ELGN-GI (recombinant human insulin), an innovative oral formulation for the treatment of intestinal malabsorption, that causes feeding intolerance in preterm infants.

            Lead Product(s): Recombinant Human Insulin

            Therapeutic Area: Gastroenterology Product Name: ELGN-GI

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: European Innovation Council

            Deal Size: $2.5 million Upfront Cash: Undisclosed

            Deal Type: Funding July 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bekinda (formerly known as RHB-102) is a proprietary, bimodal release, once-daily oral pill formulation of the antiemetic drug ondansetron, targeting several gastrointestinal indications.

            Lead Product(s): CAS 103639-04-9

            Therapeutic Area: Gastroenterology Product Name: Bekinda

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bekinda (RHB-102) is a proprietary, oral, bi-modal extended-release (24 hours), once-daily pill formulation of the 5-HT3 receptor antagonist antiemetic drug ondansetron.

            Lead Product(s): CAS 103639-04-9

            Therapeutic Area: Gastroenterology Product Name: Bekinda

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Study result for ELGN-GI, indicate improvement in GI function and, reduction in complication, include reduction in time until life threatening central line can be removed, reduction in hospital stay, and reduction in number of life-threatening necrotizing enterocolitis events.

            Lead Product(s): Recombinant Human Insulin

            Therapeutic Area: Gastroenterology Product Name: ELGN-GI

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035. Opaganib also undergoing two oncology Phase 2 U.S. studies as well as several development programs for inflammatory and viral indications, including Ebola.

            Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

            Therapeutic Area: Gastroenterology Product Name: RHB-104

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.

            Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

            Therapeutic Area: Gastroenterology Product Name: RHB-104

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering March 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.

            Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

            Therapeutic Area: Gastroenterology Product Name: RHB-204

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Public Offering January 11, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY